(n= 107) (n=57) 5  2  30-7  35-13  3  40-11  2  45-18  5   50-10  5   55-8  18  60-16  16  65-6  16  70-3  16  75-3  9  80-3  85-5 plantation or dialysis, even though the survival rate is 10-15% shorter than that in non-diabetic subjects. These results represent a considerable advance. A third of the patients, however, died without renal support treatment. Some deaths, notably from acute myocardial infarction, were probably unavoidable, and a few patients (10) were over 75 years of age. The rest died from renal failure alone or renal failure complicated by "cardiac failure," which presumably indicated fluid retention. Many of these patients could probably have been successfully treated and fluid retention and "cardiac failure" alleviated if renal support had been given at an appropriately earlier stage of their disease. This neglect should not occur nowadays. In the past many reasons were given for assigning patients as "unsuitable" for renal support treatment3; most of these are no longer valid and only dementia, senility, carcinomatosis, and occasionally multiple overwhelming disorders should lead to exclusion. Blindness alone should not preclude patients from receiving such treatment.
25-
In future diabetic patients with nephropathy should be attended jointly by diabetic and renal physicians working together. Considerable attention must be given at an early stage to the detection and treatment of major vascular disease to pre-empt as far as possible the development of problems during renal support treatment.4 All diabetic patients with nephropathy should now be considered for such treatment, which should be started either when fluid retention or other uraemic features develop or when glomerular filtration is usually less than 20 ml/minute and the serum creatinine concentration greater than 450 tmol/l.
We thank the many physicians who helped with this survey and completed two or sometimes three questionnaires.
The figure) , advised that their partners should seek treatment, and urged to return for follow up. Of the 8002 women aged 16-45 registered during the study year, 120 requested referral for abortion. The age specific rates for women aged 16-24, 25-34, and 35-44 years were 22, 18, and 3 per 1000 respectively. Altogether, 103 women were recruited to the study, 12 of whom had chlamydia infection but no symptoms or clinical signs. The figure shows the outcomes for the women.
A total of 96 women had a termination, of whom nine consulted within three weeks for serious problems connected with the abortion. Five of the nine had an infection of the upper genital tract and four were readmitted with retained products of conception. All the women treated for chlamydial cervicitis remained symptomless. Eight were negative at follow up and three who were in good health refused follow up tests. None of the five women with upper genital tract infection had received antibiotics before the abortion. 
Comment
This patient's acute renal failure developed after an operation on the aorta, infusion of Gelofusine, and considerable changes in the serum albumin concentration. We cannot exclude the possibility that the renal failure was secondary to a transient reduction in renal perfusion pressure; indeed, this may be the explanation for the fall in urine output during the operation that led to the infusion of the Gelofusine. Nevertheless, the changes in the serum albumin concentration despite a normal plasma oncotic pressure suggest that Gelofusine accumulated in this patient and that it is potentially nephrotoxic.
There are many similarities between Gelofusine and the dextran solutions, which are well recognised causes of renal failure.2 Both types of solutions are made up of molecules of varying sizes that are largely filtered by the kidneys and will precipitate when concentrated, and both solutions are hyperoncotic compared with plasma. The nephrotoxicity of dextran solutions probably depends on the presence of additional factors such as reduced renal perfusion pressure and diminished rates of urine flow, both of which favour the BMJ VOLUME 299
